Headshots of researchers involved in the BANDIT trial in new onset diabetes
Research Spotlight

Groundbreaking study finds JAK inhibitor baricitinib slows type 1 diabetes progression

World-first study findings by Australian researchers show a daily pill containing the JAK inhibitor baricitinib can preserve insulin production in people newly diagnosed with T1D. Published in the December issue of the New England Journal of Medicine, findings were co-authored by Thomas Kay, MBBS, PhD,  and Helen Thomas, PhD, St.

Read more
Blue background featuring a collage of photos from research participants. Text in the image reads "a message to our TrialNet family" and "celebrating 2023"
Media Release

Celebrating a New Era in Type 1 Diabetes Research - A Message from TrialNet Chair Kevan C. Herold, MD

TrialNet Chair Kevan C. Herold, MD, Yale University, reflects on key accomplishments of the past year and shares direction for 2024 and beyond.

Dear TrialNet family,

As we start the new year, I want to take time to recognize TrialNet’s major achievements in 2023 and share our direction for advancing type 1 diabetes (T1D) research in the year ahead.

Read more
Orlando Brown, Jr. speaks to reporters in front of a blue JDRF backdrop with orange and white ballons
Participant Spotlight

NFL Super Bowl Champion Orlando Brown, Jr. hosts JDRF event in Cincinnati – encourages T1D family members to get screened, help advance science

Photo courtesy of JDRF Southern & Central Ohio Chapter

During what proved to be an unforgettable celebration by the JDRF community in Cincinnati, NFL Super Bowl Champion and Bengals offensive lineman Orlando Brown, Jr. encouraged relatives of people with type 1 diabetes (T1D) to get screened by TrialNet to help advance research.

Read more

Sign up here to join our mailing list for the latest updates on important T1D research and events, straight to your inbox. You can also find us on Facebook @DiabetesTrialNet.